Durvalumab + Tremelimumab + Gemcitabine + Cisplatin
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Resectable Carcinoma
Conditions
Borderline Resectable Carcinoma, Biliary Tract Cancer
Trial Timeline
Dec 1, 2024 → Nov 1, 2026
NCT ID
NCT06017297About Durvalumab + Tremelimumab + Gemcitabine + Cisplatin
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin is a phase 2 stage product being developed by AstraZeneca for Borderline Resectable Carcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06017297. Target conditions include Borderline Resectable Carcinoma, Biliary Tract Cancer.
What happened to similar drugs?
0 of 4 similar drugs in Borderline Resectable Carcinoma were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06017297 | Phase 2 | Withdrawn |
Competing Products
12 competing products in Borderline Resectable Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 40 |
| olanzapine | Eli Lilly | Pre-clinical | 26 |
| Olanzapine | Eli Lilly | Phase 3 | 40 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 40 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 35 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 40 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 35 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 29 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 36 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 33 |
| vafidemstat + Placebo | Oryzon Genomics | Phase 2 | 25 |